読み込み中
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
前日終値
$9.46
+$0.17 · +1.83%
市場前
$9.40
−$0.06 · -0.63%
10月12日 8:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
日中レンジ
現在 $9.46
52週レンジ
現在 $9.46
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
37
割高
センチメント
71
強気
リスク
39
中程度のリスク
モメンタム
79
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
日中レンジ
現在 $9.46
52週レンジ
現在 $9.46
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 1625.86万 USD | 1129.27万 USD | 873.5万 USD | 419.58万 USD | 12.65万 USD |
| 販売・一般管理 | 1369.78万 USD | 1138.2万 USD | 740.61万 USD | 402.32万 USD | 122.55万 USD |
| 営業費用 | 2995.64万 USD | 2267.47万 USD | 1614.11万 USD | 821.89万 USD | 135.2万 USD |
| 受取利息 | 55.55万 USD | 101.74万 USD | 57.2万 USD | — | — |
| 支払利息 | — | — | — | 497 USD | 17.99万 USD |
| 減価償却費と償却費 | 36.45万 USD | 11.54万 USD | 5468 USD | 2135 USD | 2468 USD |
| 営業利益 | −2995.64万 USD | −2267.47万 USD | −1614.11万 USD | −821.89万 USD | −135.2万 USD |
| 純利益 | −2943.86万 USD | −2161.34万 USD | −1542.6万 USD | −822.97万 USD | −2438.39万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$23.33
上昇余地（146.62%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2498.03万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1937.2万0.20%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1458.01万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF966.72万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO510.48万0.04%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO331.27万0.02%180億 USD0.06%$112.66+0.50%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS241.84万0.61%3.99億 USD0.60%$107.24+1.40%
iShares Micro-Cap ETFIWC174.82万0.13%13.17億 USD0.60%$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
